Top approved MS therapies in the U.S. by ARR 2014
This statistic displays the major currently approved therapies for multiple sclerosis (MS) as of 2014 in the United States, by annualized relapse rate (ARR). During this year, EMD Serono's Rebif, approved in 2002, had an ARR of 32 percent. There are about 350,000 to 500,000 people in the country that are diagnosed with the disease. MS is a disease that damages nerve cells in the brain and spinal cord which disrupts the ability of the nervous system to communicate with the body.
